TW518337B - Method for the preparation of pure carboxyethyl germanium sesquioxide - Google Patents
Method for the preparation of pure carboxyethyl germanium sesquioxide Download PDFInfo
- Publication number
- TW518337B TW518337B TW87119493A TW87119493A TW518337B TW 518337 B TW518337 B TW 518337B TW 87119493 A TW87119493 A TW 87119493A TW 87119493 A TW87119493 A TW 87119493A TW 518337 B TW518337 B TW 518337B
- Authority
- TW
- Taiwan
- Prior art keywords
- germanium
- reaction mixture
- reaction
- sesquioxide
- products
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
518337 經濟部中央標準局員工消費合作社印製 A7 B7五、發明説明(6 ) ch3 ch3 ί ! GeCl4 + HSi - OSiH + H2C=C-C02H........... ! ί I CH3 ch3 h Η H ! ! Cl3Ge - C · |C - C〇2h +丙嫌酸鍺反應產物 Η Η +揮發性副產物 (ΤΡΑ) 步驟2 - 關於一有利實體中之第二步驟,第一混合物受到真空 蒸餾以除去揮發性副產物。有利的真空是約0 · 1 To r r至約25To r r,更有利地自約0 · 5 To r r至約5To :r r。此真空蒸餾之內部溫度是約 6 0 °C至約7 5 °C。以蒸餾導致第二反應混合物,其實質 由T P A加丙烯酸鍺反應產物組成。此步驟之反應流程是 Η Η CI3G- - C - C - C02H ^反應產物 蒸餾 ί ! +揮發性副產物.................. Η Η Η Η ί ι -Cl^Ge ' C, * V C〇2H " 丙嫌酸鍺反應產物 t i Η Η (ΤΡΑ) 步驟3 在一有利實體中,第二反應混合物其次與Η c 1反應 (請先閱讀背面之注意事項再本頁)518337 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs A7 B7 V. Invention Description (6) ch3 ch3 ί! GeCl4 + HSi-OSiH + H2C = C-C02H ........... ί I CH3 ch3 h Η H!! Cl3Ge-C · | C-C〇2h + germanium propionate reaction product Η Η + volatile by-product (TPA) Step 2-Regarding the second step in a favorable entity, the first mixture is subjected to Vacuum distillation to remove volatile by-products. An advantageous vacuum is from about 0.1 Torr to about 25Torr, and more advantageously from about 0.5Torr to about 5To: rr. The internal temperature of this vacuum distillation is about 60 ° C to about 75 ° C. Distillation leads to a second reaction mixture consisting essentially of the reaction product of TP A plus germanium acrylate. The reaction flow in this step is Η Η CI3G--C-C-C02H ^ Distillation of the reaction product! + Volatile by-products ........ Η Η Η Η ί ι -Cl ^ Ge 'C, * VC〇2H " The reaction product of germanium propionate ti Η Τ (TPA) Step 3 In an advantageous entity, the second reaction mixture reacts with Η c 1 (please read the first (Notes on this page)
訂 線· 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -9 - 丙烯酸鍺反應產物 + HC1 (濃縮)---------> 經濟部中央標準局員工消費合作杜印製 518337 A7 _ B7 五、發明説明(7 ) ,後者之量是至少足以與丙烯酸鍺反應產物反應以致鍺反 應產物轉化成TPA。因此,此步驟得到TPA與HC 1 之混合物。HC 1之有利的量是約0 · 2 5至約1 0質量 當量氯化鍺之質量比較),且最有利地約0 · 5至 約3質量當量。反應之有利溫度是約6 0 °C至約8 5 °C ’ 且反應之有利時間是約3 0分鐘至約4小時,最有利地約 4 5分鐘至約9 0分鐘。此結果是第三混合物,其實質由 T P A白色固體及水性濃縮的Η- C 1的鹵化混合物組成。 此步驟之反應流程是: Η Η I ! c - c - co2h I jAlignment · This paper size applies to Chinese National Standard (CNS) A4 (210X297 mm) -9-Germanium Acrylic Acid Reaction Product + HC1 (Concentrated) --------- > Staff Consumption of Central Standards Bureau, Ministry of Economic Affairs Cooperative Du printed 518337 A7 _ B7 5. Description of the invention (7), the amount of the latter is at least enough to react with the reaction product of germanium acrylate so that the reaction product of germanium is converted to TPA. Therefore, in this step, a mixture of TPA and HC 1 is obtained. An advantageous amount of HC 1 is a mass comparison of about 0.25 to about 10 mass equivalents of germanium chloride), and most advantageously about 0.5 to about 3 mass equivalents. A favorable temperature for the reaction is about 60 ° C to about 85 ° C 'and a favorable time for the reaction is about 30 minutes to about 4 hours, most advantageously about 45 minutes to about 90 minutes. This result is a third mixture consisting essentially of a TP A white solid and a halogenated mixture of aqueous concentrated rhenium-C1. The reaction flow of this step is: Η Η I! C-c-co2h I j
Η H Η ΚΗ H Η Κ
Cipe - C · C: - COzH + HC1 (濃縮) : i ' Η Η (TPA) 步驟4 在一有利實體中之其下步驟中,第三混合物受到溶劑 萃取以分離氫氯酸與T P A,因此產生第四混合物,其實 質由T P A及萃取溶劑組成。足以萃取所有的H C 1之量 的合適萃取溶劑包括鹵化的溶劑如氯仿及四氯化碳,及有 利地,二氯甲烷。在萃取中所用之鹵化溶劑的量是約1至 約3 0質量當量(與四氯化鍺之起始質量比較),且最有 利約3至約8質量當量。有利地使用過多量之萃取溶劑以 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐)-10 - 請 先 閲 讀 背 意 項 頁 518337 A7 B7 五、發明説明(1〇 ) 量相對於T P A晶體是1質量當量溶劑。 步驟9及1 〇 在一有利實體中之最終步驟中,純的τ P A晶體而後 在迴流條件下,伴著逐步添加少量之蒸餾水而反應。、少 量〃意謂僅添加足量之蒸餾水以使晶體溶入溶液中。蒸餾 水之有利的量約1 5至約2 5質量當.量(與TPA質量相 比)。有利的內部溫度是約7 °C至約1 0 0 °C。迴流時 間有利地是約1至約3小時。晶體溶解後,停止蒸餾水之 添加,且溶液冷卻至周溫且靜置至少約1 2小時,且最有 利地約2 4小時至4 8小時。結果是純的鍺倍半氧化物固 體,其而後使用重力濾器或濾紙(如Watman #4紙)或使用 抽吸過濾(漏斗型),使用濾紙(如Watman #2紙)來過濾 。經過濾之溶液而後順序地用水,丙酮及,最後地,醚來 洗。水洗液是約1質量當量(與Τ P A相比)至約1 0質 量當量,更有利地,約2至約4質量當量。丙酮洗液是約 1至約10質量當量(與TPA相比),有利地約2至約 4質量當量。最終,醚洗液是約1至約1 〇質量當量(與 TPA相比),且有利地,約2至約4質量當量。純羧乙 基鍺倍半氧化物之化學式是G e 2C4H1Q〇7。 而後可以使用經純化離析之羧乙基鍺倍半氧化物於, 例如,飮食補充物中以給予上述之健康益處。本發明之羧 乙基鍺倍半氧化物製法之一益處是其提供一種安全且有效 的鍺形式以供人體使用。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)-13 - (請先閲讀背面之注意事項再Cipe-C · C:-COzH + HC1 (concentrated): i 'Η Η (TPA) Step 4 In the next step in an advantageous entity, the third mixture is subjected to solvent extraction to separate hydrochloric acid from TPA, thus producing The fourth mixture consists essentially of TPA and an extraction solvent. Suitable extraction solvents in an amount sufficient to extract all of the H C 1 include halogenated solvents such as chloroform and carbon tetrachloride, and advantageously, dichloromethane. The amount of halogenated solvent used in the extraction is about 1 to about 30 mass equivalents (compared to the starting mass of germanium tetrachloride), and most preferably about 3 to about 8 mass equivalents. Advantageously use too much extraction solvent to comply with Chinese National Standard (CNS) A4 specification (210X297 mm) at this paper size. -10-Please read the back page first page 518337 A7 B7 V. Description of the invention (1〇) TPA crystals are 1 mass equivalent solvent. Steps 9 and 10 In a final step in an advantageous entity, pure τ PA crystals are then reacted under reflux conditions with a small amount of distilled water gradually added. A small amount means adding only enough distilled water to dissolve the crystals into the solution. An advantageous amount of distilled water is about 15 to about 25 mass equivalents (compared to the TPA mass). A favorable internal temperature is about 7 ° C to about 100 ° C. The reflux time is advantageously about 1 to about 3 hours. After the crystals are dissolved, the addition of distilled water is stopped, and the solution is cooled to ambient temperature and left to stand for at least about 12 hours, and most advantageously about 24 hours to 48 hours. The result is a pure germanium sesquioxide solid, which is then filtered using gravity filters or filter paper (such as Watman # 4 paper) or suction filtration (funnel type) and filter paper (such as Watman # 2 paper). The filtered solution was washed sequentially with water, acetone and, finally, ether. The water washing liquid is about 1 mass equivalent (compared to TP A) to about 10 mass equivalent, and more advantageously, about 2 to about 4 mass equivalent. The acetone wash is about 1 to about 10 mass equivalents (compared to TPA), and advantageously about 2 to about 4 mass equivalents. In the end, the ether wash is about 1 to about 10 mass equivalents (compared to TPA), and advantageously about 2 to about 4 mass equivalents. The chemical formula of pure carboxyethylgermanium sesquioxide is Ge 2C4H1Q07. The purified and isolated carboxyethylgermanium sesquioxide may then be used in, for example, a dietary supplement to give the aforementioned health benefits. One of the benefits of the carboxyethylgermanium sesquioxide process of the present invention is that it provides a safe and effective form of germanium for human use. This paper size applies to China National Standard (CNS) A4 (210X297mm) -13-(Please read the precautions on the back before
訂 經濟部中央標準局員工消費合作社印製 518337 經濟部中央標準局員工消費合作杜印製 A7 B7五、發明説明(11 ) 特別地,本發明消除了鍺金屬可進入飮食補充物之可 能性,因爲起始材料及方法並無產生任何鍺金屬之潛在性 。此外,本發明消除了二氧化鍺引入飮食補充物中之潛在 性,該補充物合倂有本發明方法所製之羧乙基鍺倍半氧化 物。此有二主要理由。首先,上述方法之再結晶步驟消除 了任何先前步驟所可能產生之任何二氧化鍺。其次,本發 明方法即用以消除任何二氧化鍺,即使在再結晶步驟前。 特定地,在本發明方法中所存在之任何二氧化鍺會僅以第 一反應步驟中所用之四氯化鍺的副產物方式存在。換言之 ,在四氯化鍺與四甲基乙矽氧烷及丙烯酸之起始反應中, 理論上可能存留有未反應之四氯化鍺,其潛在地能水解成 二氧化鍺。但是,真空蒸餾之第二步驟會除去任何殘存之 未反應的四氯化鍺,藉此防止另外之二氧化鍺經由水解而 形成。即使任何二氧化鍺以副產物形式殘存於水相中,此 種二氧化鍺經由隨後之方法的萃取及蒸餾步驟而除去且丟 棄。例如,在方法中之其下步驟(亦即在上述有利實體中 之第三步驟),與氫氯酸之反應會將任何二氧化鍺副產物 轉化成四氯化鍺。若在蒸餾及萃取步驟後仍存留任何二氧 化鍺,其在用鹵化之溶劑之溶劑萃取的其下步驟期間會觀 察爲固體,因爲二氧化鍺不溶於鹵化溶劑中。因爲沒有觀 察到二氧化鍺,明顯地二氧化鍺不存在於有機相中。再者 ,其下之真空蒸餾步驟會除去任何因H C 1及二氧化鍺之 反應所產生之四氯化鍺,,藉此消除任何四氯化鍺或二氧化 鍺殘存於反應混合物中之可能性。結果,本發明方法提供 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐)-14 - (請先閱讀背面之注意事項再本頁)Ordered by the Consumer Standards Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs, printed 518337 Printed by the Consumer Standards Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs, printed by A7 B7 V. Invention Description (11) In particular, the present invention eliminates the possibility that germanium metal can enter food supplement Because the starting materials and methods do not have any potential for germanium metal. In addition, the present invention eliminates the potential for the introduction of germanium dioxide into a dietary supplement that incorporates a carboxyethylgermanium sesquioxide produced by the method of the present invention. There are two main reasons for this. First, the recrystallization step of the above method eliminates any germanium dioxide that may have been produced by any previous step. Second, the method of the invention is used to eliminate any germanium dioxide, even before the recrystallization step. In particular, any germanium dioxide present in the process of the invention will only exist as a by-product of the germanium tetrachloride used in the first reaction step. In other words, in the initial reaction of germanium tetrachloride with tetramethylethoxysilane and acrylic acid, theoretically there may be unreacted germanium tetrachloride, which can potentially hydrolyze to germanium dioxide. However, the second step of vacuum distillation removes any remaining unreacted germanium tetrachloride, thereby preventing the formation of additional germanium dioxide through hydrolysis. Even if any germanium dioxide remains in the water phase as a by-product, such germanium dioxide is removed and discarded by subsequent extraction and distillation steps of the method. For example, in the next step in the process (ie, the third step in the advantageous entity described above), the reaction with hydrochloric acid will convert any germanium dioxide by-product to germanium tetrachloride. If any germanium dioxide remains after the distillation and extraction steps, it will be observed as a solid during the next step of extraction with a solvent of a halogenated solvent, because germanium dioxide is insoluble in the halogenated solvent. Since no germanium dioxide was observed, it was clear that germanium dioxide was not present in the organic phase. Furthermore, the vacuum distillation step below will remove any germanium tetrachloride produced by the reaction of HC 1 and germanium dioxide, thereby eliminating any possibility that germanium tetrachloride or germanium dioxide remains in the reaction mixture. . As a result, the method of the present invention provides that the paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) -14-(Please read the precautions on the back before this page)
訂 線· 518337 A7 B7 五、發明説明(12 ) 一種充份充之羧乙基鍺倍半氧化物產物以供人類消耗。 請 先 閲 讀 背 之 注 意 事 項 本發明之羧乙基鍺倍半氧化物之製法具有其它優點。 例如,本發明提供高產率之純的羧乙基鍺倍半氧化物。” 高產率〃意謂比普通之產通羧乙基鍺倍半氧化物之方法, 有約1 0%至2 0%之純的羧乙基鍺倍半氧化物之產率的 增加。再者,本發明方法有可能可以比普通方法得到高於 2 0%之產率增加。本發明之另一優點是其避免使用苛性 ,毒性且危險的化學品(如氫氧化銨和硫酸),這些係使 用於一般之合成鍺的方法中。此外,本方法,比先前已知 之方法,如那些於美國專利第5,504,225及 5,386,046中所述者,使用實質更少量的HC 1 。結果,本發明方法具有生態益處且可以節省實質量之時 間,勞力及來源於製造方法中。 經濟部中央標準局員工消費合作社印製 使用羧乙基鍺倍半氧化物據了解亦對人類健康有助益 。對每日健康之維持而言,建議約1 Omg/天至約 2 0 〇mg/天至約2 0 Omg/天之劑量範圍。爲了治 療先前存在之健康狀態,例如流行感冒症候,每日固體劑 型是約10mg/天至約1〇,〇〇〇mg/天。對於一 用於治療先前存在之狀況的注射溶液而言,鍺倍半氧化物 的量是約10mg/天至約1,〇〇〇mg/天,且有利 地,約30mg/天至約300mg/天。 本發明之羧乙基鍺倍半氧化物組成物是安定的化合物 且可與其它之飮食補充物成份結合。這些製劑可以用一般 方法製成。爲製備本發明之組成物,依一般混合技術,各 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)-15 - 518337 A 7 __B7 五、發明説明(13 ) 成份在一次製備中以中間摻合物中之活性成份形式結合以 合適之載劑或賦形劑。本發明組成物與一般所用之賦形劑 如麥芽糖糊精及微晶性纖維素是相容的。 依所要之投服的製劑形式,如口部,舌下,鼻或非經 腸的,合適的載體可以有廣泛的形式。 在製備口服劑型之組成物中,可以使用任何一般的醫 藥介質。對口服液體製劑(如懸濁液,糖漿及溶液)而言 ,可以使用含有例如水,油,醇,芳香劑,防腐劑,著色 劑等之介質。可以使用載劑如澱粉,糖,稀釋劑,成粒劑 ,潤滑劑,粘合劑,崩解劑等以製備口服之固體(如粉末 ,明膠膠囊,九及錠劑)。明膠膠囊是有利的口服劑型。 也可以使用錠劑,微封之錠劑及其它經控制釋出型。因爲 易於投服,錠劑,錠,九及膠囊代表最有利之口服劑量單 位型,其中顯然地利用了固態醫藥載劑。若想要,錠劑可 用標準技術來加糖衣,腸衣或微封。 對非經腸產物而言,載劑常包括無菌水,雖然可以包 括其它成份以例如幫助溶解性或保存目的。也可以製備注 射懸濁液,在此情況中,可以利用合適的液態載劑,懸浮 劑等。 作爲上述方法之可選擇的實體,可改變下述步驟,其 中·· (1 )第一步驟之反應時間可以從約7天增至介於約 3 0天至約1 2 0天之間,且有利地約4 5天; (2 )在第三步驟中所用之濃氫氯酸的量可減少; 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -16 - 請 先 閲 讀 背 面 之 注 意 項Ordering · 518337 A7 B7 V. Description of the invention (12) A sufficient carboxyethyl germanium sesquioxide product for human consumption. Please read the note below. The method for preparing carboxyethylgermanium sesquioxide according to the present invention has other advantages. For example, the present invention provides high yields of pure carboxyethylgermanium sesquioxide. "High yield" means that the yield of pure carboxyethylgermanium sesquioxide is increased by about 10% to 20% compared to the ordinary method of producing carboxyethylgermanium sesquioxide. Furthermore, It is possible that the method of the present invention can obtain a yield increase of more than 20% than the ordinary method. Another advantage of the present invention is that it avoids the use of harsh, toxic and dangerous chemicals (such as ammonium hydroxide and sulfuric acid). These systems It is used in general methods of synthesizing germanium. In addition, this method uses substantially smaller amounts of HC 1 than previously known methods, such as those described in U.S. Patent Nos. 5,504,225 and 5,386,046. As a result, the method of the present invention has ecological benefits and can save real quality time, labor and origin from the manufacturing method. The use of carboxyethylgermanium sesquioxide printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economics is also known to be beneficial to human health It is helpful. For the maintenance of daily health, a dosage range of about 10 mg / day to about 200 mg / day to about 200 mg / day is recommended. In order to treat pre-existing health conditions, such as influenza symptoms , The daily solid dosage form is About 10 mg / day to about 10,000 mg / day. For an injection solution for treating a pre-existing condition, the amount of germanium sesquioxide is about 10 mg / day to about 1,000. mg / day, and advantageously, about 30 mg / day to about 300 mg / day. The carboxyethylgermanium sesquioxide composition of the present invention is a stable compound and can be combined with other dietary supplement ingredients. These preparations can It is made by the general method. In order to prepare the composition of the present invention, according to the general mixing technology, each paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) -15-518337 A 7 __B7 V. Description of the invention (13 ) The ingredients are combined in a single preparation as the active ingredient in an intermediate blend with a suitable carrier or excipient. The composition of the present invention is compatible with commonly used excipients such as maltodextrin and microcrystalline cellulose Appropriate carriers can be used in a wide range of formulations, such as oral, sublingual, nasal or parenteral, as required. In the preparation of oral dosage forms, any general medicine can be used. Medium. For oral liquid preparations For suspensions, syrups, and solutions), media containing, for example, water, oil, alcohol, fragrance, preservatives, colorants, etc. can be used. Carriers such as starch, sugar, diluents, granulating agents, Lubricants, binders, disintegrating agents, etc. to prepare oral solids (such as powders, gelatin capsules, nine tablets, and lozenges). Gelatin capsules are advantageous oral dosage forms. Lozenges, microencapsulated lozenges, and other Controlled release. Because of ease of administration, lozenges, lozenges, capsules, and capsules represent the most advantageous oral dosage unit type, which obviously utilizes solid pharmaceutical carriers. If desired, lozenges can be sugar-coated using standard techniques For parenteral products, carriers often include sterile water, although other ingredients may be included to aid solubility or preservation purposes, for example. Injection suspensions can also be prepared, in which case suitable liquid carriers, suspending agents and the like can be utilized. As an optional entity of the above method, the following steps can be changed, where (1) the reaction time of the first step can be increased from about 7 days to between about 30 days and about 120 days, and Advantageously about 4 5 days; (2) the amount of concentrated hydrochloric acid used in the third step can be reduced; this paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) -16-please read the back first Notes
頁 經濟部中央標準局員工消費合作社印製 518337 經濟部中央標準局員工消費合作社印製 A7 B7五、發明説明(15 ) 固體被過濾且再懸浮於3 0毫升蒸餾水中,而後加熱 至回流直至混合物變爲均勻。此溶液而後回流4小時,而 後冷卻至周溫,藉此羧乙基鍺倍半氧化物在約4 8小時之 期間形成。1色羧乙基鍺倍半氧化物固體經抽吸過濾來離 析,順序地用2x5·4升丙酮,及2x5·4升乙醚淸 洗。所得之明亮的白色羧乙基鍺倍半氧化物固體在4 0°C 下之真空爐中乾燥過夜。 實例2 在5 0升玻璃反應器中順·序地添加7 2克四氯化鍺, 5 · 3kg四甲基乙矽氧烷,及2 · 32kg丙烯酸,且 所得反應混合物攪拌5天。揮發性副產物經由真空蒸餾除 去,同時產物混合物加熱至7 5 °C至8 0°C之內部溫度, 其中它是均勻,無色,半粘稠溶液(熔融)。持續蒸餾直 至不再出現餾出液。此反應混合物冷卻至周溫,產生白色 不定形固體。 此固體而後溶在3 5升濃H C 1中。所得均勻混合物 加溫至6 0 °C - 7 0 °C之內部溫度,且攪拌4小時。冷卻 之混合物用2 5升二氯甲烷萃取3次。二氯甲烷在4 0°C 下用真空蒸餾除去以得粗製之T P A白色不定形固體。 此T P A固體立即溶入(激烈行爲),伴著小心添加 3 0升氫氧化銨(2 9%氨)。所得混合物在周溫下攪拌 4天。在此物中在2小時內經回流冷凝器逐滴添加4 0 0 毫升濃硫酸。白色T P A固體經抽吸過濾而離析,順序地 本紙張尺度適用中國國家標準(CNS )八4祕(210X297公董)-18- (請先閱讀背面之注意事項再本頁)Printed by the Consumers 'Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 518337 Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs A7 B7 V. Invention Description (15) The solid is filtered and resuspended in 30 ml of distilled water, and then heated to reflux until the mixture Becomes uniform. This solution was then refluxed for 4 hours and then cooled to ambient temperature, whereby carboxyethylgermanium sesquioxide was formed over a period of about 48 hours. The 1-color carboxyethylgermanium sesquioxide solid was isolated by suction filtration and washed sequentially with 2x5.4 litres of acetone and 2x5.4 litres of ether. The resulting bright white carboxyethylgermanium sesquioxide solid was dried in a vacuum oven at 40 ° C overnight. Example 2 In a 50-liter glass reactor, 72 g of germanium tetrachloride, 5.3 kg of tetramethylethoxysilane, and 2.32 kg of acrylic acid were sequentially added, and the resulting reaction mixture was stirred for 5 days. The volatile by-product was removed by vacuum distillation, while the product mixture was heated to an internal temperature of 75 ° C to 80 ° C, where it was a homogeneous, colorless, semi-viscous solution (melted). Continue distillation until no more distillate appears. The reaction mixture was cooled to ambient temperature to give a white amorphous solid. This solid was then dissolved in 35 liters of concentrated H C 1. The resulting homogeneous mixture was warmed to an internal temperature of 60 ° C-70 ° C and stirred for 4 hours. The cooled mixture was extracted three times with 2.5 liters of dichloromethane. Dichloromethane was removed by vacuum distillation at 40 ° C to obtain crude TPA white amorphous solid. This TP A solid dissolved immediately (violent behavior) with careful addition of 30 liters of ammonium hydroxide (29% ammonia). The resulting mixture was stirred at ambient temperature for 4 days. To this was added 400 ml of concentrated sulfuric acid dropwise over a reflux condenser over a period of 2 hours. White T P A solids were isolated by suction filtration, and this paper size was in accordance with Chinese National Standard (CNS) Eighty-fourth Secret (210X297), 18- (Please read the precautions on the back before this page)
01T 線 518337 A7 B7 五、發明説明(16 ) ,2x5 · 4升水,2x5 · 4升丙酮及2x5 · 4升乙醚 淸洗,而後此明亮的白色純T P A固體受空氣乾燥過夜。 此純的T P A固體溶入9升熱蒸餾水中,而後冷卻且過濾 以產生羧乙基鍺倍半氧化物。 實例3 使用有機羧乙基鍺倍半氧化物之.食物補充物之例示性 混合物是: ~ (請先閲讀背面之注意事項再_馬本頁)01T line 518337 A7 B7 5. Description of the invention (16), 2x5 · 4 liters of water, 2x5 · 4 liters of acetone and 2x5 · 4 liters of ether, and then the bright white pure TP A solid was dried by air overnight. This pure TP A solid was dissolved in 9 liters of hot distilled water, then cooled and filtered to produce carboxyethylgermanium sesquioxide. Example 3 Using an organic carboxyethylgermanium sesquioxide. An exemplary mixture of a food supplement is: ~ (Please read the precautions on the back first, then the _ page)
Pangamic 酸 羧乙基鍺倍半氧化物* Co-Enzyme Q 1 0 維生素A 維生素E 維生素D 維生素K 5 0 m g 2 5 m g 2 5 m g 1,2 5 0 I 10 0 1 . U 7 . 5 I . U 1 2 5 m gPangamic Acid Carboxyethyl Germanium Sesquioxide * Co-Enzyme Q 1 0 Vitamin A Vitamin E Vitamin D Vitamin K 50 mg 2 5 mg 2 5 mg 1, 2 5 0 I 10 0 1. U 7.. 5 I. U 1 2 5 mg
U 訂 線 經濟部中央標準局員工消費合作社印製 *羧乙基鍺倍半氧化物可以藉上述本發明之任一方法製備 雖然本發明之特別實體已於本文中描述及闡明,應了 解修飾及變異對那些精於此技藝者是易於發生的,且因此 申請專利範圍企圖涵蓋被說明成此種修飾及相等物。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)_ 19 ·U Printed by the Central Consumers Bureau of the Ministry of Economic Affairs, printed by the Consumer Cooperative of the Company * Carboxyethylgermanium sesquioxide can be prepared by any of the methods of the present invention described above. Mutations are prone to those skilled in the art, and therefore the scope of the patent application is intended to cover such modifications and equivalents. This paper size applies to China National Standard (CNS) A4 (210X297 mm) _ 19 ·
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/977,516 US5919964A (en) | 1994-03-02 | 1997-11-24 | Method for the preparation of pure carboxyethyl germanium sesquioxide |
Publications (1)
Publication Number | Publication Date |
---|---|
TW518337B true TW518337B (en) | 2003-01-21 |
Family
ID=27805711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW87119493A TW518337B (en) | 1997-11-24 | 1998-11-24 | Method for the preparation of pure carboxyethyl germanium sesquioxide |
Country Status (1)
Country | Link |
---|---|
TW (1) | TW518337B (en) |
-
1998
- 1998-11-24 TW TW87119493A patent/TW518337B/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10538507B2 (en) | Preparation process for high-purity dabigatran etexilate | |
EP3115356A1 (en) | Polymorphs of bromfenac sodium and methods for preparing bromfenec sodium ploymorphs | |
TW518337B (en) | Method for the preparation of pure carboxyethyl germanium sesquioxide | |
FR2684382A1 (en) | Pure preparations and medicaments of melarsomine dihydrochloride, process for their preparation and intermediates obtained | |
CN101583586B (en) | Improvement in synthesis of butylated hydroxyanisole from tertiary butyl hydroquinone | |
TW528742B (en) | Process for preparing (1R, 2S, 4R)-(-)-2-[(2'-(N,N-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof | |
CN1374310A (en) | Prepn process of sodium cantharidinate | |
RU2599788C2 (en) | New polymorphic form of a calciemetric compound | |
JP2005506969A (en) | Novel modification of trometamol salt of R-thioctic acid and its production | |
CN102180864B (en) | Preparation method of strontium ranelate | |
US5919964A (en) | Method for the preparation of pure carboxyethyl germanium sesquioxide | |
JPS63295561A (en) | 2-quinolone derivative | |
US5550266A (en) | Method for the preparation of pure carboxyethyl germanium sesquioxide | |
EP0344737B1 (en) | Process for purifying alpha-substituted acetic acids | |
TW449596B (en) | Process for preparing crystalline loracarbef monohydrate | |
JPH04112848A (en) | Crystalline magnesium valproate and its manufacture | |
HU196603B (en) | Process for producing n-(phosphonomethyl)-glycine | |
US5703259A (en) | Method for the preparation of pure carboxyethyl germanium sesquioxide | |
CN110903230B (en) | Industrial preparation method of pramipentane sulfate | |
CN103124719B (en) | Process for the synthesis of diclofenac choline salt | |
JP2003096038A (en) | Production method of high-purity n-long chain acylamino acid or salt thereof | |
EP0539460A1 (en) | Salts derived from dialkylaminoalkylsulphonyl-26 pristinamycin ii b. | |
JPS63297347A (en) | Production of chloroalkylamine | |
CN111440069A (en) | Synthesis process of disalicylate | |
US20040069208A1 (en) | Process for crystallizing enantiomerically enriched 2-acetylthio-3-phenylpropionic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MK4A | Expiration of patent term of an invention patent |